Heart valve trial: fix both leaks at once or just one?

NCT ID NCT07349888

Not yet recruiting Disease control Sponsor: Nanjing First Hospital, Nanjing Medical University Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study will enroll 404 people with severe leakage in both the mitral and tricuspid heart valves. Participants will be randomly assigned to have either both valves repaired at once using a catheter-based device, or only the mitral valve repaired. The goal is to see which approach leads to better survival, fewer heart-related hospital stays, and improved quality of life over one year.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Transcatheter Edge-to-Edge Repair (TEER) device
What this could lead to: If it works, this could show that repairing both leaky heart valves at once is better than fixing only one, leading to fewer hospital visits and better quality of life for patients.
What could go wrong: This trial hasn't started yet, and it's not a cure—patients will still need lifelong medication. The procedure itself carries risks like bleeding or valve damage, and the benefit over standard care is unproven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MITRAL REGURGITATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

mitral valve insufficiency tricuspid valve insufficiency

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MITRAL REGURGITATION TRICUSPID REGURGITATION

More trials for these conditions

Other studies related to the condition(s) this trial covers.